The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Abstract

Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19 antibody linked via sulfo-SPDB to the potent DNA-alkylating agent DGN462. huB4-DGN462 had improved in vitro anti-proliferative and cytotoxic activity compared to SAR3419 across multiple B-cell lymphoma and human acute lymphoblastic leukemia cell lines. In vivo experiments using lymphoma xenografts models confirmed the in vitro data. The response of B-cell lymphoma lines to huB4-DGN462 was not correlated with CD19 expression, the presence of BCL2 or MYC translocations, TP53 inactivation or lymphoma histology. In conclusion, huB4-DGN462 is an attractive candidate for clinical investigation in patients with B-cell malignancies.

Two Retrospective Analyses Show No Associated Adverse Outcomes With Delayed RP

“…[3][4][5]12 However, previous data do not demonstrate that the use of IMT increases the risk of other viral pneumonias, such as influenza. 17 Therefore, statement B is also correct. Yet it is known that in  Figure 3.…”

Development of Therapeutic Antibody Technology And Recent Perspectives For Leukemia-Lymphoma Treatment

“…Based on vitro and vivo B cell malignancy study report, the novel CD19 targeting antibody drug conjugate hub4-dgn462 showed significant improvements in anti-tumor activity CD19-positive lymphoma-leukemia models .This would provide a best option for the near future of B cell malignancy therapy using antibody drug conjugates [69].…”

Advances in targeted therapy for malignant lymphoma

“…116 A novel ADC based on coltuximab ravtansine showed promising preclinical data and may become an attractive candidate for clinical investigation. 117 Loncastuximab tesirine (ADCT-402) is a novel CD19-targeted ADC that delivers SG3199, a highly cytotoxic pyrrolobenzodiazepine dimer, and showed highly targeted cytotoxicity in vitro and antitumor activity in vivo in preclinical studies. 118 A pivotal phase 2 study (NCT03589469) is currently ongoing on relapsed or refractory DLBCL, as well as phase 1 studies (NCT02669017, NCT03684694, and NCT03685344) on relapsed or refractory B-NHLs.…”